Methylphenidate and stuttering.

Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for Attention Deficit Hyperactivity Disorder. Studies concerning stuttering occurring with methylphenidate are contradictory. We investigated the association between methylphenidate and stuttering. We analyzed reports in the World Health Organization global individual case safety reports database, Vigibase, up to 31 December 2018, with the MedDRA Preferred Term "dysphemia" and the Lower Level Terms "stutter" and "stuttering". The association between exposure to MPH and occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting Odds Ratios (ROR) were calculated with 95% Confidence Intervals (CIs). In total, 2,975 cases of dysphemia were reported, of which 46 reports were associated with MPH. For the PT "dysphemia", the ROR was 7.3 (95% CI: 5.4-9.8). With the LLT "stuttering", 584 cases were registered in the database of which 17 involved MPH. The ROR was 13.9 (95% CI: 8.6-22.5). This study found a signal for stuttering with methylphenidate.

• Publication year

  2019

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2019-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bcp.14097PMID 31418914PMCID PMC6848957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Methylphenidate and stuttering.

  2019cited by this paper
• Expectation effects on brain dopamine responses to methylphenidate in cocaine use disorder

  2019cited by this paper
• Emergence of stuttering in an attention deficit hyperactivity disorder patient treated with methylphenidate

  2018cited by this paper
• The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention‐deficit/hyperactivity disorder and other psychiatric comorbidities

  2018influential reference
• Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

  2018cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY

  2017cited by this paper
• Shifted dynamic interactions between subcortical nuclei and inferior frontal gyri during response preparation in persistent developmental stuttering

  2017cited by this paper
• Stuttering: Clinical and research update.

  2016cited by this paper
• Effect of dopaminergic medication on speech dysfluency in Parkinson’s disease: a longitudinal study

  2015cited by this paper
• Stuttering Associated With the Use of Short-Acting Oral Methylphenidate.

  2015cited by this paper
• Influence of Methylphenidate on the Frequency of Stuttering

  2015cited by this paper
• Prevalence of Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis

  2015cited by this paper
• A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD)

  2014cited by this paper
• Global Patterns of Adverse Drug Reactions Over a Decade

  2012cited by this paper
• Comparative effects of zinc, selenium and vitamin E or their combination on carbohydrate metabolizing enzymes and oxidative stress in streptozotocin induced-diabetic rats.

  2012cited by this paper
• Methylphenidate as a treatment for stuttering: a case report.

  2012cited by this paper
• Methylphenidate-Elicited Dopamine Increases in Ventral Striatum Are Associated with Long-Term Symptom Improvement in Adults with Attention Deficit Hyperactivity Disorder

  2012influential reference
• VigiBase, the WHO Global ICSR Database System: Basic Facts

  2008cited by this paper
• The application of knowledge discovery in databases to post‐marketing drug safety: example of the WHO database

  2008cited by this paper
• Under-Reporting of Adverse Drug Reactions

  2006cited by this paper
• Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.

  2003cited by this paper
• Application of data mining techniques in pharmacovigilance.

  2003cited by this paper
• Management of Child and Adolescent Stuttering with Olanzapine: Three Case Reports

  1999influential reference
• Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment

  1999cited by this paper
• Increased dopamine activity associated with stuttering

  1997cited by this paper
• Stuttering and stimulants.

  1991influential reference

• Methylphenidate-Induced Stuttering in a Patient With Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder: A Case Report.

  2025cites this paper
• Sertraline-Induced Stuttering in an Adolescent with Autism Spectrum Disorder

  2024influential citation
• Adult stuttering prevalence I: Systematic review and identification of stuttering in large populations.

  2024cites this paper
• [Stuttering in Children: Review and Referral Criteria].

  2023cites this paper
• Drug-Induced Stuttering: Occurrence and Possible Pathways

  2021cites this paper
• Speech Fluency Disorders: A Review of Studies Conducted Over the Past Five Decades (1970-2020)

  2021cites this paper
• Drug induced stuttering: pharmacovigilance data

  2020cites this paper
• Methylphenidate and stuttering.

  2019cites this paper
• Methylphenidate-induced stuttering

  2019cites this paper